Free Trial
NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Price, News & Analysis

Corcept Therapeutics logo
$72.30 +0.82 (+1.15%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$73.28 +0.98 (+1.36%)
As of 08/8/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Corcept Therapeutics Stock (NASDAQ:CORT)

Key Stats

Today's Range
$71.60
$73.08
50-Day Range
$67.17
$76.77
52-Week Range
$33.34
$117.33
Volume
666,838 shs
Average Volume
886,694 shs
Market Capitalization
$7.62 billion
P/E Ratio
63.98
Dividend Yield
N/A
Price Target
$134.50
Consensus Rating
Buy

Company Overview

Corcept Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

CORT MarketRank™: 

Corcept Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 72nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Corcept Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Corcept Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Corcept Therapeutics are expected to grow by 36.03% in the coming year, from $1.36 to $1.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corcept Therapeutics is 63.98, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corcept Therapeutics is 63.98, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.01.

  • Price to Book Value per Share Ratio

    Corcept Therapeutics has a P/B Ratio of 11.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Corcept Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.96% of the float of Corcept Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Corcept Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Corcept Therapeutics has recently decreased by 2.01%, indicating that investor sentiment is improving.
  • Dividend Yield

    Corcept Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Corcept Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.96% of the float of Corcept Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Corcept Therapeutics has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Corcept Therapeutics has recently decreased by 2.01%, indicating that investor sentiment is improving.
  • News Sentiment

    Corcept Therapeutics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Corcept Therapeutics this week, compared to 12 articles on an average week.
  • Search Interest

    Only 5 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,221,432.00 in company stock.

  • Percentage Held by Insiders

    20.80% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corcept Therapeutics' insider trading history.
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

CORT Stock Analysis - Frequently Asked Questions

Corcept Therapeutics' stock was trading at $50.39 at the beginning of the year. Since then, CORT stock has increased by 43.5% and is now trading at $72.30.

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings data on Thursday, July, 31st. The biotechnology company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.06. The firm's quarterly revenue was up 18.7% compared to the same quarter last year.
Read the conference call transcript
.

Corcept Therapeutics' top institutional investors include Ingalls & Snyder LLC (7.28%), Parallel Advisors LLC (3.65%), Geode Capital Management LLC (1.82%) and TD Asset Management Inc (0.77%). Insiders that own company stock include Joseph K Belanoff, Hazel Hunt, Gary Charles Robb, Joseph Douglas Lyon, Sean Maduck, William Guyer, David L Mahoney and Daniel N Swisher, Jr.
View institutional ownership trends
.

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Intel (INTC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
7/31/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CORT
CIK
1088856
Employees
300
Year Founded
1998

Price Target and Rating

High Price Target
$145.00
Low Price Target
$121.00
Potential Upside/Downside
+86.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.13
Trailing P/E Ratio
63.98
Forward P/E Ratio
53.16
P/E Growth
N/A
Net Income
$141.21 million
Net Margins
18.51%
Pretax Margin
17.63%
Return on Equity
20.10%
Return on Assets
16.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.06
Quick Ratio
2.98

Sales & Book Value

Annual Sales
$675.04 million
Price / Sales
11.29
Cash Flow
$1.26 per share
Price / Cash Flow
57.55
Book Value
$6.03 per share
Price / Book
11.99

Miscellaneous

Outstanding Shares
105,370,000
Free Float
83,455,000
Market Cap
$7.62 billion
Optionable
Optionable
Beta
0.20

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CORT) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners